$ARCC

Analysts reiterated Buy ratings for Ares Capital (ARCC) and Cypherpunk Technologies (CYPH). ARCC has a $20.50 target (Bank of America) and $23.50 target (TipRanks), with shares near $19.92. CYPH has a $1.60 target (Cantor Fitzgerald), with shares at $1.42. Both have Strong Buy/Moderate Buy consensus.

Ares Capital filed a document with the SEC addressing shareholder claims. The filing details the company's compliance efforts. No specific financial figures were disclosed. The update may impact investor perceptions of Ares Capital's governance and risk management.

Ares Management Corp. is leading a $2.2 billion loan to MedImpact Holding Inc. to finance its acquisition of Medical Card System, Inc. The second-lien loan may pay at least 8% over the baseline rate. Ares manages $671 billion in assets and recently reported $708 billion in non-accruing loans. MedImpact serves 20 million customers and processes $40 billion in pharmacy transactions annually.

Private credit markets are showing increasing signs of distress, with non-accrual debt rising among the largest BDCs. In Q2, non-accrual debt at the top 10 BDCs increased to 3.95% of total debt, up from 3.75% in Q1. The broader BDC universe also saw a rise in non-accrual borrowers, reaching 4.69% in Q1 2026. Adjusted non-accrual rates are higher, indicating wider credit stress. Interest income at risk is climbing, potentially impacting BDC yields.

Ares Capital (ARCC) and Main Street Capital (MAIN) reported low non-accrual loans and strong earnings, positioning them for potential Fed rate hikes. ARCC's non-accruals were 2.4% of amortized cost, below the median, and it maintains $6B in liquidity. MAIN's non-accruals were 1.1% at fair value, and its NAV rose to $33.92 per share. Both offer high yields, near 10% for ARCC and high single digits for MAIN.

Ares Capital (ARCC), the largest BDC, offers a 9.8% dividend yield, maintained for 16 years. It invests in 619 middle-market companies, with 63% in secured loans. Analysts expect EPS to decline 5% this year but rise 1% by 2027, potentially covering its dividend. ARCC's performance depends on interest rates balancing its income and portfolio companies' health.

MetLife (MET) and Realty Income (O) show divergent reactions to 30-year Treasury yields at 5.31%. MET benefits from higher yields, with Q1 2026 net investment income up 10% and dividends raised twice. O faces yield competition, though fundamentals remain solid. Other dividend stocks like ARCC, VNO, and VZ are also impacted by debt structures and refinancing costs.

ARES CAPITAL CORP (ARCC) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. Item 5.07 Submission of Matters to a Vote of Security Holders . Special Meeting of Stockholders On August 13, 2026, Ares Capital Corporation (the “Company”) held its special meeting of stockholders (the “Special Meeting”). The issued and outstanding shares of stock of the Company

Investing.com reports private credit BDCs have fallen 10-18% over the past year but rebounded 5-12% in the last month. It cites dividend yields of 7-12.6% and shows 1Y and 1M performance for BXSL, BIZD, HTGC, MAIN, ARCC, GBDC, and BBDC. It notes RBC maintained Outperform on KBDC but cut its price target to $15 from $16.

Reuters reports mixed updates in U.S. private credit. Apollo Global said redemption requests for its $26 billion Apollo Debt Solutions fund eased to about half the prior level, after investors sought ~16.8% redemptions versus a 5% maximum. BCP Investment and Morgan Stanley Direct Lending Fund posted weaker Q2 results, while Ares Management shrank a planned €1 billion vehicle. Golub Capital repurchase requests fell to 4.8%.